- Home
- MCRB vs SAVA Comparison
MCRB vs SAVA Comparison
Compare MCRB & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- SAVA
- Stock Information
- Founded
- MCRB 2010
- SAVA 1998
- Country
- MCRB United States
- SAVA United States
- Employees
- MCRB N/A
- SAVA N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- MCRB Health Care
- SAVA Health Care
- Exchange
- MCRB Nasdaq
- SAVA Nasdaq
- Market Cap
- MCRB 144.8M
- SAVA 157.5M
- IPO Year
- MCRB 2015
- SAVA N/A
- Fundamental
- Price
- MCRB $16.87
- SAVA $2.76
- Analyst Decision
- MCRB Hold
- SAVA Buy
- Analyst Count
- MCRB 3
- SAVA 2
- Target Price
- MCRB $14.33
- SAVA $5.00
- AVG Volume (30 Days)
- MCRB 88.5K
- SAVA 1.3M
- Earning Date
- MCRB 11-05-2025
- SAVA 11-12-2025
- Dividend Yield
- MCRB N/A
- SAVA N/A
- EPS Growth
- MCRB N/A
- SAVA N/A
- EPS
- MCRB 0.62
- SAVA N/A
- Revenue
- MCRB $351,000.00
- SAVA N/A
- Revenue This Year
- MCRB N/A
- SAVA N/A
- Revenue Next Year
- MCRB N/A
- SAVA N/A
- P/E Ratio
- MCRB $26.91
- SAVA N/A
- Revenue Growth
- MCRB N/A
- SAVA N/A
- 52 Week Low
- MCRB $6.53
- SAVA $1.15
- 52 Week High
- MCRB $24.67
- SAVA $33.98
- Technical
- Relative Strength Index (RSI)
- MCRB 51.80
- SAVA 37.26
- Support Level
- MCRB $12.48
- SAVA $2.79
- Resistance Level
- MCRB $14.35
- SAVA $3.30
- Average True Range (ATR)
- MCRB 1.18
- SAVA 0.22
- MACD
- MCRB 0.22
- SAVA -0.08
- Stochastic Oscillator
- MCRB 80.50
- SAVA 0.47
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.